Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLS2702C/CLS2702D cell sheet transplantation after ESD for superficial esophageal cancer (steroid risk group)
jRCT2063200048Phase 3Completed
- Sponsor
- CellSeed
- Start
- Feb 2021
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of CLS2702C/CLS2702D oral mucosal epithelial cell sheet in esophageal cancer and Esophageal stricture, sponsored by CellSeed. Primary endpoint: Proportion of subjects without stenosis. Started Feb 2021; status: completed.
02
Drugs
CLS2702C/CLS2702D oral mucosal epithelial cell sheet
03
Conditions
esophageal cancerEsophageal stricture
Beyond the preview
Go deeper on jRCT2063200048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2063200048.